Silvia Noiman

Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022.

Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States.

cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel.

Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels.

Pontifax Management Co. Ltd. (Pontifax) is a venture capital firm founded in 2004 by Eliyahu Hurvitz. The firm is headquartered in Herzliya Pituach, Israel.

Quiet Therapeutics Ltd. develops a proprietary nanoparticle-based delivery system for the targeted delivery of chemotherapy and anti-inflammatory drugs. It developed a class of cancer therapeutics called GAGomers, enables the flexibility of delivering a medicine that can kill the cancer cells and block the production of proteins that promote the cancer. The company was founded by Dan Peer and Rimona Margalit in 2009 and is headquartered in Ness Ziona, Israel.

Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel.